Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market Report 2026

Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market Overview

• Urine Tumor Deoxyribonucleic Acid (DNA) Testing market size has reached to $1.18 billion in 2025 • Expected to grow to $2.36 billion in 2030 at a compound annual growth rate (CAGR) of 14.9% • Growth Driver: Surge In Urological Cancers Fueling The Growth Of The Market Due To Aging Populations And Rising Cancer Incidence • Market Trend: Enhancing Diagnostic Accuracy Through Standardized Urine Sample Workflows • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market?

Urine tumor deoxyribonucleic acid (DNA) testing is a diagnostic method that analyzes DNA fragments shed by cancer cells into the urine. It helps detect genetic mutations and alterations associated with tumor development and progression. This testing enables non-invasive monitoring of cancer presence, recurrence, and response to treatment. The main technologies of urine tumor deoxyribonucleic acid (DNA) testing include PCR-based, next-generation sequencing, and others. PCR-based refers to methods or tests that utilize polymerase chain reaction to amplify specific DNA or RNA sequences for detection, analysis, or research purposes. The various product types include assay kits, instruments, and services. They are used for cancer types including bladder cancer, prostate cancer, kidney cancer, and other cancer types, and compatible with sample types such as first-morning urine, random urine samples, and catheterized urine samples. The key end-use include hospitals, diagnostic laboratories, research institutes, and other end-users.

What Is The Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market Growth Forecast?

The urine tumor deoxyribonucleic acid (DNA) testing market size is expected to see rapid growth in the next few years. It will grow to $2.36 billion in 2030 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to ai-driven urine dna analysis, development of multiplex and high-throughput assays, expansion of personalized medicine, integration with electronic health records, rising demand for non-invasive monitoring solutions. Major trends in the forecast period include non-invasive cancer monitoring, liquid biopsy advancements, ai-powered genetic analysis, high-sensitivity urine dna detection, integration with clinical decision support systems.

Global Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market Segmentation

1) By Technology: Polymerase Chain Reaction-based, Next-Generation Sequencing, Other technologies 2) By Product Type: Assay Kits, Instruments, Services 3) By Cancer Type: Bladder Cancer, Prostate Cancer, Kidney Cancer, Other Cancer Types 4) By Sample Type: First-Morning Urine, Random Urine Samples, Catheterized Urine Samples 5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutes, Other End-Users Subsegments: 1) By Polymerase Chain Reaction Based: Real Time Polymerase Chain Reaction, Digital Polymerase Chain Reaction, Multiplex Polymerase Chain Reaction, Reverse Transcription Polymerase Chain Reaction 2) By Next Generation Sequencing: Whole Genome Sequencing, Targeted Gene Sequencing, Exome Sequencing, Transcriptome Sequencing 3) By Other Technologies: Microarray Based Testing, Hybridization Based Assays, Mass Spectrometry Based Analysis, Fluorescence In Situ Hybridization

What Is The Driver Of The Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market?

The increasing prevalence of urological cancers is expected to drive the growth of the urine tumor deoxyribonucleic acid (DNA) testing market in the coming years. Urological cancers affect the urinary system and male reproductive organs, including the kidneys, bladder, prostate, and testes, and their incidence is rising largely due to aging populations, as cancer risk increases with advancing age. Urine tumor DNA testing supports the management of urological cancers by enabling the non-invasive detection of cancer-specific genetic mutations in urine, facilitating early diagnosis, disease monitoring, and personalized treatment planning. For instance, in December 2025, according to Cancer Australia, an Australia-based government department, an estimated 28,868 new prostate cancer cases were diagnosed, accounting for approximately 30% of all new cancer diagnoses among men. Therefore, increasing prevalence of urological cancers is expected to drive the growth of the urine tumor deoxyribonucleic acid (DNA) testing industry.

Key Players In The Global Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market

Major companies operating in the urine tumor deoxyribonucleic acid (DNA) testing market are Roche Diagnostics, Thermo Fisher Scientific Inc., Abbott Laboratories, Illumina Inc., QIAGEN N.V., Bio-Techne Corporation, NeoGenomics Laboratories Inc., Freenome Holdings Inc., MDxHealth SA, Biodesix Inc., Sysmex Inostics GmbH, Pacific Edge Limited, Apostle Inc., Lucence Diagnostics, Pangea Laboratory, Nucleix Ltd, Genomica Lab, Vesica Health, Biocept Inc., Promis Diagnostics Inc.

Global Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market Trends and Insights

Major companies operating in the urine tumor deoxyribonucleic acid (DNA) testing market are increasingly focused on developing advanced solutions such as urine-based liquid biopsy platforms to enable non-invasive cancer detection, improve diagnostic accuracy, and support personalized treatment planning. Urine-based liquid biopsy platforms are non-invasive diagnostic systems designed to detect and analyze tumor-derived DNA and other biomarkers from urine samples for cancer detection, monitoring, and disease progression assessment. For instance, in September 2024, PreAnalytiX, a joint venture between QIAGEN, a Netherlands-based sample-to-insight provider, and Becton, Dickinson and Company, a US-based medical technology firm, launched a novel urine-based liquid biopsy solution designed to enable high-quality DNA stabilization and extraction for downstream molecular analyses. Developed to support both clinical and research applications, the platform features standardized urine collection, efficient DNA preservation, and compatibility with next-generation sequencing workflows, facilitating early cancer detection, accurate biomarker assessment, and improved patient management.

What Are Latest Mergers And Acquisitions In The Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market?

In October 2024, Pangea Laboratory, a US-based provider of urine-based tumor DNA testing services, partnered with Unilabs to expand access to its Bladder CARE Assay. Through this partnership, the companies aim to make the Bladder CARE Assay available in Switzerland and across Europe, enabling non-invasive detection of bladder cancer through urine tumor DNA testing. Unilabs is a Switzerland-based provider of advanced molecular cancer diagnostics, including liquid biopsy and molecular residual disease (MRD) testing, supporting the broader adoption of innovative oncology diagnostics.

Regional Insights

North America was the largest region in the urine tumor deoxyribonucleic acid (DNA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market?

The urine tumor deoxyribonucleic acid (DNA) testing market consists of revenues earned by entities by providing services such as data interpretation, reporting and consultation, and quality control and assurance. The market value includes the value of related goods sold by the service provider or included within the service offering. The urine tumor deoxyribonucleic acid (DNA) testing market includes sales of storage tubes, sample transport containers, and analysis instruments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data And Analysis Are Included In The Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market Report 2026?

The urine tumor deoxyribonucleic acid (dna) testing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the urine tumor deoxyribonucleic acid (dna) testing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.